​

Bicara Therapeutics Ownership | Who Owns Bicara Therapeutics?

OverviewForecastFinancialsChartTranscripts

Bicara Therapeutics Ownership Summary

Bicara Therapeutics is owned by 119.37% institutional investors, 10.07% insiders. Ra capital management is the largest institutional shareholder, holding 11.95% of BCAX shares. T. Rowe Price US Small-Cap Core Equity is the top mutual fund, with 3.27% of its assets in Bicara Therapeutics shares.

BCAX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBicara Therapeutics119.37%10.07%-29.44%
SectorHealthcare Stocks 50.50%12.33%37.17%
IndustryBiotech Stocks 49.09%12.06%38.85%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management7.26M11.95%$215.43M
T. rowe price investment management6.34M10.44%$188.19M
Siren5.60M9.23%$166.35M
Vestal point capital, lp5.25M8.65%$155.87M
Deep track capital, lp4.10M6.75%$121.73M
Blackrock funding, inc. /de3.85M6.34%$114.25M
Janus henderson group3.33M6.08%$66.11M
Red tree management3.16M5.21%$93.92M
Tpg gp a3.01M4.96%$89.38M
Vanguard group2.19M4.01%$36.79M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Red tree management3.16M63.77%$93.92M
Omega fund management1.82M29.14%$54.10M
Acorn capital advisors643.38K5.21%$19.10M
Vestal point capital, lp5.25M3.64%$155.87M
Aisling capital management lp568.92K3.58%$16.89M
Siren5.60M3.37%$166.35M
Superstring capital management lp175.90K2.74%$2.78M
Palo alto investors lp550.41K2.26%$16.34M
Ra capital management7.26M1.87%$215.43M
Tpg gp a3.01M1.79%$89.38M

Top Buyers

HolderShares% AssetsChange
Blackrock funding, inc. /de3.85M0.00%1.00M
Jpmorgan chase1.02M0.00%838.56K
Janus henderson group3.33M0.03%680.63K
State street2.05M0.00%629.53K
Price t rowe associates inc /md/1.90M0.01%528.05K

Top Sellers

HolderShares% AssetsChange
Braidwell lp---2.16M
Deerfield management company, l.p. (series c)---1.80M
Citadel advisors211.14K0.00%-1.45M
Wellington management group llp---1.39M
Adage capital partners gp---1.18M

New Positions

HolderShares% AssetsChangeValue
Sixth street partners management company365.48K0.00%365.48K$10.85M
Cantor fitzgerald, l. p.100.00K0.01%100.00K$1.58M
Rhenman & partners asset management ab88.15K0.25%88.15K$2.62M
Exoduspoint capital management, lp53.88K0.01%53.88K$850.80K
Norges bank42.89K0.00%42.89K$721.82K

Sold Out

HolderChange
Sbi securities-1.00
Aster capital management (difc)-1.00
Quadrant capital group-13.00
Mrp capital investments-20.00
Root financial partners-29.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202618016.88%72,477,8081.71%1190.70%11022.22%39-2.50%
Mar 31, 202678-45.83%15,246,758-73.87%270.24%48-46.67%17-51.43%
Dec 31, 202592-19.30%27,836,301-44.55%510.60%57-12.31%23-14.81%
Sep 30, 20251115.71%49,553,927-3.15%901.03%64-18.99%2662.50%
Jun 30, 202510519.32%51,165,42915.59%931.42%7946.30%16-

Top Mutual Funds Shareholders

HolderShares% HoldingChange
T. Rowe Price US Small-Cap Core Equity2.15M3.27%-33.46K
T. Rowe Price Small-Cap Stock2.15M3.27%-31.91K
Vanguard Total Stock Mkt Idx Inv1.68M2.55%305.30K
Vanguard Morn Total Stk Mkt Idx Investor1.68M2.55%305.30K
T. Rowe Price Instl Small-Cap Stock1.16M1.76%-13.52K
iShares Russell 2000 ETF1.12M1.71%-19.97K
State Street® SPDR® S&P® Biotech ETF1.08M1.64%2.48K
T. Rowe Price U.S. SC Core Eq Tr-D1.00M1.53%-29.85K
Fidelity Select Biotechnology944.90K1.44%-
Franklin Biotechnology Discv A(acc)USD778.96K1.19%113.72K

Recent Insider Transactions

DateNameRoleActivityValue
Aug 10, 2026Hyep Ivan Chief Financial OfficerSell$349.59K
Aug 10, 2026Mazumdar Claire Chief Executive OfficerSell$279.75K
Aug 10, 2026Cohlhepp Ryan President and COOSell$524.53K
Jul 10, 2026Mazumdar Claire Chief Executive OfficerSell$831.04
Jul 10, 2026Mazumdar Claire Chief Executive OfficerSell$283.37K

Insider Transactions Trends

DateBuySell
2026 Q3-12
2026 Q2-10
2026 Q1221
2025 Q4-23
2025 Q3-2

BCAX Ownership FAQ

Who Owns Bicara Therapeutics?

Bicara Therapeutics shareholders are primarily institutional investors at 119.37%, followed by 10.07% insiders and -29.44% retail investors. The average institutional ownership in Bicara Therapeutics's industry, Biotech Stocks , is 49.09%, which Bicara Therapeutics exceeds.

Who owns the most shares of Bicara Therapeutics?

Bicara Therapeutics’s largest shareholders are Ra capital management (7.26M shares, 11.95%), T. rowe price investment management (6.34M shares, 10.44%), and Siren (5.6M shares, 9.23%). Together, they hold 31.62% of Bicara Therapeutics’s total shares outstanding.

Does Blackrock own Bicara Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Bicara Therapeutics.

Who is Bicara Therapeutics’s biggest shareholder by percentage of total assets invested?

Red tree management is Bicara Therapeutics’s biggest shareholder by percentage of total assets invested, with 63.77% of its assets in 3.16M Bicara Therapeutics shares, valued at 93.92M$.

Who is the top mutual fund holder of Bicara Therapeutics shares?

T. Rowe Price US Small-Cap Core Equity is the top mutual fund holder of Bicara Therapeutics shares, with 3.27% of its total shares outstanding invested in 2.15M Bicara Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools